Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results, Beats Expectations By $0.08 EPS

Tarsus Pharmaceuticals (NASDAQ:TARS) announced its quarterly earnings data on Tuesday. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.08, Zacks reports. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%.

Tarsus Pharmaceuticals Stock Down 4.8 %

TARS opened at $45.54 on Tuesday. The stock has a fifty day moving average of $51.75 and a 200-day moving average of $42.90. The company has a market capitalization of $1.74 billion, a P/E ratio of -11.95 and a beta of 1.01. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Barclays boosted their target price on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Guggenheim reissued a “buy” rating on shares of Tarsus Pharmaceuticals in a research report on Monday. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Finally, The Goldman Sachs Group increased their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $56.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.